SUMMARY
INTRODUCTION
Measurement of anti-glycolipid antibodies is a relatively new diagnostic test. Antibodies against more than 20 different gangliosides have now been associated with a wide range of clinical entities, including a number of acute and chronic peripheral neuropathies [1] . Depending on the types of neuropathy, different anti-ganglioside antibodies are observed. Anti-ganglioside antibodies can be detected using several methods, either qualitative or quantitative. All of them have advantages and drawbacks. Laboratories can measure levels of anti-gan-____________________________________________ Manuscript accepted January 10, 2013 glioside antibodies in serum using thin-layer chromatography (TLC) overlay [2] [3] [4] , enzyme linked immunesorbent assay (ELISA) [2] [3] [4] , agglutination tests [5, 6] , flow cytometry [7] , and in-house [8] [9] [10] [11] [12] or commercial immunodot or immunoline assays [13, 14] . These approaches differ substantially in their accuracy, sensitivity and specificity. Several parameters, such as: incubation at 4°C rather than room temperature, high background values due to non-specific binding, detergent treatment, purity of gangliosides from different commercial sources, coating process of gangliosides, and cut-off values to discriminate between patients and controls, may influence the assessment of serum anti-ganglioside antibodies by immunoassays [16] . There is an increased need for simple, multi-parametric detection of anti-ganglioside antibodies to diagnose immune-mediated peripheral neuropathies. The "accepted reference" TLC overlay is carried out in specialized laboratories and is not routinely available. The same limitation applies to our in-house immunoassay validated by TLC [8] [9] [10] [11] [12] . There is a clear demand for replacement of inhouse anti-ganglioside antibody detection methods by commercial tests which need validation before routine clinical use. A great variability in the frequency of IgM or IgG anti-GM1 antibodies detected by ELISA assays has been observed, either in the same laboratory or between laboratories [16] . There is still no consensus on the most effective and the most reproducible procedure to use. IgG and IgM antibodies bound to dominant gangliosides may react equally or preferentially with other related gangliosides. Since commercial tests are now in widespread use, we thought that it was critical to determine their diagnostic performance. A key issue is the number of target antigens included in each commercial assay as it has been shown that a large panel of gangliosides is essential to correctly identify complex antibody profiles specific for patients with Guillain-Barré syndrome or its variants [12] or with chronic ataxic neuropathy with ophthalmoplegia, M-paraprotein, cold agglutinins, and disialosyl antibodies (CANOMAD) syndrome [2] . Until now, the reliability of anti-ganglioside antibody measurements provided by different tests has not been evaluated appropriately and the results obtained in different laboratories are difficult to compare. Moreover, the current accreditation process in our laboratory requires the selection of the best available test. Therefore, we investigated the performance of anti-ganglioside antibody detection in clinical practice by four commercial tests. We analyzed the concordance of the results by comparing them with those obtained with our in-house dot test. Patients with CANOMAD syndrome were selected according to their specific anti-ganglioside antibody profiles as our group is currently involved in the establishment of the French national registry of CANOMAD syndrome.
MATERIALS AND METHODS

Sera and patient selection
Sera with high levels of anti-ganglioside antibodies from 33 patients with immune-mediated peripheral neuropathy, previously tested in our laboratory and stored at -20°C, were selected based on positivity in the inhouse IDA. Sera were collected from 15 patients with acute peripheral neuropathies showing Guillain-Barré syndrome and related variants including 6 patients with acute motor (AMAN) and motor sensory axonal neuropathies (AM-SAN), 4 with typical Miller Fisher syndrome (SMF), 2 patients with GBS with ophthalmoplegia, 2 with CMV induced GBS demonstrating IgM anti-GM2 antibodies, and 1 patient with Campylobacter jejuni induced GBS showing IgM antibodies. Furthermore, 18 patients with chronic peripheral neuropathies were enrolled into the study including 12 patients with CANOMAD syndrome demonstrating all clinical and serological characteristics of the syndrome reported by Willison [2] , 4 patients with motor chronic neuropathies associated with monoclonal IgM (M-IgM) antibodies, 1 patient with chronic sensory neuropathy with M-IgM antibodies, and 1 with multifocal motor neuropathy demonstrating persistent conduction block. The control sera were obtained from 10 patients with non-autoimmune neuropathy i.e., without anti-ganglioside, anti-myelin associated glycoprotein (MAG), and anti-sulfatide antibody presence, confirmed by in-house immunoassay. Six patients suffered from amyotrophic lateral sclerosis (ALS) and 4 from pure axonal chronic sensory neuropathies due to metabolic disorders.
Anti-ganglioside antibody assays Anti-ganglioside antibody by in-house immunodot assay The antibodies to gangliosides were detected by our validated IDA technique described elsewhere [8] [9] [10] [11] [12] . It was the first test developed in 1993 employing a hydrophobic membrane as solid phase and was validated by TLC. Briefly, IgG and IgM anti-ganglioside antibodies against a panel of bovine purified gangliosides were detected on a hydrophobic, solvent resistant polyvinylidene difluoride (PVDF) membrane (PVDF-P, Millipore, Saint-Quentin, France). The immobilization of 8 gangliosides (GM3, GM2, GM1, GD3, GD1a, GD1b, GT1b, and GQ1b), sulfatide, and galactocerebroside (Sigma, St Louis, MO, USA; Calbiochem, VWR International SAS, France) at 1 µg of each ganglioside and 0.1 µg of sulfatide and galactocerebroside in a volume of 1 µL in methanol allowed the detection of a large spectrum of antibodies on the same membrane stripe. The patient and control sera were diluted 1/100 and 1/200 and incubated for 2 hours at 2 -8°C while shaking. The secondary antibody, alkaline phosphatase-conjugated F(ab')2 fragment goat anti-human IgG and IgM (Jackson Immuno Research Laboratories/Interchim France), was incubated for 1.5 hours at 2 -8°C while shaking.
Sigma substrate fast tablets containing nitroblue tetrazolium in a bromochloro-indolylphosphate buffer (NBT/ BCIP) were used to detect the enzyme reaction at 25°C. Incubation conditions and times are given in Table 1 . Sensitivity and specificity have been determined as reported elsewhere [9] .
Anti-ganglioside antibody immunoline assay from Generic Assays, Dahlewitz, Germany/Eurobio, Courtaboeuf, France (Test 1) The Anti-GangliosidDot is a line immunoassay used for the qualitative detection of IgG + IgM, IgG or IgM antibodies to gangliosides in serum or plasma. The kit contains 20 numbered strips with a positive control line, bovine sulfatide, and 11 highly purified human gangliosides (GM1, GM2, GM3, GM4, GD1a, GD1b, GD2, GD3, GT1a, GT1b, GQ1b). All components are ready-for-use except the incubation buffer. 10 µL of the samples are added to 1 mL of sample diluent in each channel containing the strips (final dilution 1:101). Incubation conditions and times are given in Table 1 . A colored line is scored positive when it is more intense than the corresponding band on the lot-specific evaluation template (cut-off control lines for every ganglioside).
Anti-ganglioside antibody immunodot assay from Dotzen-Zentec®, Angleur, Belgium/ Ingen, ChiliMazarin, France (Test 2) Dotzen ® Ganglio Profile Ab is an IDA for the determination of IgG and IgM or IgG + IgM autoantibodies against 9 gangliosides in human serum including GM1, GM2, GM3, GD1a, GD1b, GD3, GT1a, GT1b, GQ1b, and sulfatide (24 determinations). A sample predilution of 1+100 is required. 250 µL of the prediluted samples are added to 1 mL of sample diluent in each channel containing the strips (final dilution 1:501). Incubation conditions and times are given in Table 1 . Dried and glued strips are interpreted after 30 minutes by visual examination.
Anti-ganglioside antibody by immunoline assay: Euroline from Euroimmun Lübeck, Germany/Bioadvance, Bussy Saint Martin, France (Test 3)
The Euroline IgM and IgG Ganglioside Profiles 2 allows the determination of up to 7 autoantibodies against GM1, GM2, GM3, GD1a, GD1b, GT1b, and GQ1b (12 determinations). Membrane strips are dotted with individual lines of purified and biochemically characterized antigens. Serum samples diluted 1 to 51 are incubated 60 minutes at room temperature (RT). Incubation conditions and times are given in Table 1 . The test strips can be automatically incubated and evaluated using the Euroblot Master system and the EuroLineScan program.
Anti-ganglioside antibody by ELISA from Bühl-mann, Schönenbuch, Switzerland (Test 4)
The semi-quantative GanglioCombi ELISA detects IgG and IgM antibodies against the gangliosides GM1, GM2, GD1a, GD1b, GQ1b, and asialo-GM1. The GanglioCombi is the most frequently employed anti-ganglioside ELISA in France and probably in Europe and provides a specific ganglioside pattern. Patient sera diluted 1 to 51 are incubated for 2 hours at 2 -8°C. After washing, antibodies are detected using a monospecific antihuman IgG or an anti-human IgM immunoserum conjugated to horseradish peroxidase. Incubation conditions and times are given in Table 1 . The enzyme reaction takes 30 minutes at 18 -28°C. Results are expressed as the ratio (%) of the sample absorbance to the absorbance of a calibrator containing a high concentration of GM1 autoantibodies. Four significance thresholds have been defined: negative < 30%, grey zone 30% to 50%, positive: 50% to 100%, strongly positive: > 100%.
Methods
The study was conducted in two phases to assess the diagnostic performance of the commercial tests. First, sera with high levels of IgM or IgG anti-ganglioside antibodies were tested to establish IgG and IgM anti-ganglioside antibody profiles. The different profiles were then compared with those obtained using our in-house IDA. Second, one CANOMAD syndrome patient serum with high levels of anti-disialylated ganglioside IgM antibodies was tested at several dilutions to check the robustness and the reproducibility of the commercial tests. All sera were assessed for anti-ganglioside antibodies according to manufacturers' instructions (Table 1) . Semi-quantitative determinations were performed by serial dilutions of two sera obtained from a patient with C. jejuni infection and AMAN demonstrating IgG > IgM antibodies against GM1 and GD1b and a patient with CANOMAD syndrome showing M-IgM-lambda antibodies against disialylated gangliosides, GD1a, and GM3 (Figure 1a/1b) . The study was approved by the local ethics committee and conducted in accordance with the Helsinki declaration.
RESULTS
Test characteristics
Comparing our in-house technique with the commercial immunoassays (Table 1) , we noticed significant technical differences regarding the ganglioside targets provided. The 4 commercial assays detect antibodies against a panel of 6 to 13 glycolipids including GM1, GM2, GM3, GM4, GD1a, GD1b, GD2, GD3, GT1a, GT1b, GQ1b, sulfatide, and asialoGM1. The 5 immunodominant gangliosides GM1, GM2, GD1a, GD1b, and GQ1b are included in all tests, while anti-sulfatide antibody testing was offered only by 2 manufacturers (Tests 1 and 2). The only ELISA kit detected immunoreactivity against a more limited panel of gangliosides immobilized onto a polystyrene solid phase. All assays were performed at 4°C according to the manufacturer's rec- Spectrum of gangliosides The strips of Test 2 were not numbered and some antigen spots presented an unusual appearance with a diffuse reaction, comet tails or bull's-eye reactions (the spot appears as a dark peripheral ring) investigating anti-GM1 and anti-GD1b antibodies. The intensity of the coloration was weak compared to Test 1 and our in house-technique. Positive sera run in Test 3 gave different results compared to those using our in-house assay. Several lines were absent or the intensity of the coloration was very weak.
Test interpretation
As the panel of target antigens differs from one test to another, the results obtained on different panels of glycolipids were difficult to compare. Willison and colleagues [2] suggested that a CANOMAD syndrome patient should present IgM antibodies against GD1b, GD3, GT1b, and GQ1b, although incomplete forms of this immunological profile may occur. As 2 of the 4 commercial assays under evaluation did not cover all these gangliosides, we have considered elevated antiGQ1b IgM reactivity only as a positive finding in Tests 3 and 4. Using the same approach for all the positive samples included in our study, we defined minimal criteria for scoring a positive result (Table 3) . All weak responses with IgM anti-GM1 antibodies were interpreted negative.
Semi-quantitative determinations
Two sera, that we routinely use as internal laboratory quality controls, were serially diluted and applied for assay comparison. The internal IgG quality control was a serum from a C. jejuni infected patient with motor axonal GBS. The specific profile demonstrated IgG > IgM antibodies against immunodominant GM1 and GD1b (anti-GM1 IgG antibody titer was 1/2000 and anti-GM1 IgM antibody titer was 1/500 with a cut-off < 1/100). The immunodominant reactivity to GM1 was observed in none of the commercial tests. The corresponding reactivities obtained with Tests 2 and 3 in particular were very weak or even negative, revealing a weaker colora- Ih T  T1  T2  T3  T4  Ih T  T1  T2  T3  T4   AMAN and  AMSAN  6 IgG antibodies against GM1 > GD1b tion of the anti-GM1 dot or line compared with the coloration of the anti-GD1b equivalent.
The internal IgM quality control was a serum from a typical CANOMAD syndrome patient referred to our laboratory. The specific anti-ganglioside antibody profile detected by our in-house test showed very high levels of monoclonal IgM antibodies (IgM-lambda) (titer 1/50 000 with a cut-off < 1/100) against the b-series disialylated gangliosides GQ1b, GT1b, GD1b, and GD3 as well as against GD1a and GM3 (a-series gangliosides) (Figure 1a) . The different IgM antibody profiles obtained with the 4 commercial tests are presented in Figures 1b to 1e and summarized in Table 2 . There was a considerable variability in anti-ganglioside reactivity by the commercial assays investigated. Only 2 or 3 anti-gangliosides were identified by Tests 3 and 4 in this CANOMAD syndrome sample, whereas Test 1 covered almost all the expected anti-ganglioside antibody reactivities (except anti-GM3). Furthermore, the reproducibility and the robustness of Test 2 are not satisfactory; indeed we found defective batches with weak sensitivity (data not shown). 
Diagnostic performances
In the 33 patients with well-characterized immune-mediated peripheral neuropathies, all tests identified antibodies against more than one ganglioside, but not necessarily the expected gangliosides. This may reflect non-specific responses and the presence of cross-reactive epitopes. The IgG or IgM intensity response against each individual ganglioside was more heterogeneous than expected.
Diagnostic sensitivity
In order to compare the diagnostic sensitivity of the tests investigated, we used the minimal criteria for positivity given in Table 3 to assess the anti-ganglioside antibody response. With commercial assays (Test 2 and 3), highly specific profiles involving the 4 immunodominant disialylated gangliosides observed in sera from CANOMAD patients were not detected at all. Figures 2  and 3 show the total number of positive findings for each anti-ganglioside antibody obtained with our inhouse assay in comparison with the 4 commercial assays. Test 1 compared to our in-house assay revealed the best detection rate followed by Test 4, while Tests 2 and 3 suffered from a lack of sensitivity. In terms of result interpretation (Table 4) , using the minimum criteria for a positive finding as defined in Table 3 , Test 1 gave an excellent correlation with our in-house assay. As a matter of fact, Test 1 showed 100% consistency indicating very good strength of agreement in accordance with interrater agreement statistics (Cohen's k = 1).
Acceptable results were obtained with Test 4, except for the CANOMAD samples. Results of Tests 2 and 3 confirmed their lack of sensitivity also for this group of patients. The commercial Tests 1 and 4 were not able to reproduce the predominance of anti-GM1 IgM over antiGD1b IgM. Using the recommended positivity criteria including a wider range of ganglioside autoantibodies improves the diagnostic accuracy (Table 4) . For the semi-quantification of the IgM internal quality control, CANOMAD syndrome specific antibodies were semi-quantified by Test 1 and by our in-house method using serial dilutions. At the standard dilution, anti-disialylated ganglioside dots or lines revealed saturated colour intensities.
Diagnostic specificity
In the control group, we did not find any positive results, although weak reactions were observed with some samples against sulfatide and GM1 in Test 1. As the anti-GM1 IgM low response is considered non-specific, the respective findings were interpreted negative. Thus, the specificity reached 100% for all tests.
DISCUSSION
We tested 12 specific IgG and 21 IgM anti-ganglioside antibody profile positive serum samples identified by our in-house assay in well-characterized immune-mediated peripheral neuropathies by 4 commercial anti-ganglioside antibody assays. The specific profiles obtained with the different tests were difficult to compare. We obtained a large heterogeneity of antibody responses against different panels of ganglioside targets. The same antigens present in all tests, GM1, GM2, GQ1b, and GD1a, demonstrated variable antibody reactivity. Thus, several points needed to be considered for the interpretation of specific IgG and IgM antibody profiles in well-defined clinical entities [8] [9] [10] [11] [12] 17, 18] . First, in order to facilitate the comparison, we carefully selected sera known to have high levels of specific antibodies as established by our in-house assay and obtained from patients with an unequivocal clinical diagnosis. It is known that anti-glycolipid antibodies have a low affinity compared with anti-peptide antibodies. Consequently, it was easier to obtain an agreement on clearly positive or negative samples in order to maximize the chances of a correct interpretation. Negative results were obtained with low levels of anti-ganglioside antibodies as expected. The relevance of anti-GM1 IgM antibodies is unclear. They are found in most patients with multifocal motor conduction block neuropathy, but also in amyotrophic lateral sclerosis (ALS), chronic inflammatory demyelinating polyneuropathy (CIDP), and other varieties of neuropathies [19] . Second, ganglioside antigenic targets can be coated either on hydrophobic membranes or on polystyrene ELISA plates [20, 21] . Disease-specific antibodies presumably recognize gangliosides incorporated in cell membranes and, thus, may fail to bind to gangliosides immobilized on a non-appropriate solid phase. Our antiganglioside antibody in-house immunodot employing PVDF membrane as a solid phase appears to provide a more accurate reaction environment for anti-ganglioside antibody assessment compared to ELISA such as discussed for the assessment of similar antibody reactivities to phospholipid antigens [22, 23] . Hydrophobic PVDF membranes as solid phases seem to mimic membranous antigen/antibody interactions more efficiently [21, 22] . Third, sensitivity and specificity values obtained are biased by the choice of relevant subgroups and are presumably higher in the present study set than in actual practice. Our samples in this study were selected based on high positivity in the in-house IDA demonstrating high diagnostic performance in several studies [8] [9] [10] [11] [12] [13] [14] . The closest sensitivity compared with our in-house IDA technique was obtained with Test 1. It detects 12 types of antibodies simultaneously under identical conditions: GM1, GM2, GM3, GM4, GD1a, GD1b, GD2, GD3, GT1a, GT1b, GQ1b, and sulfatide. It has been shown previously that detecting a wide range of ganglioside autoantibodies improves the diagnostic accuracy [17] . Moreover, Test 1 allows the detection of antibodies against recently discovered novel antigenic determinants (GD2, GM3, GM4). By offering a panel of 6 disialylated gangliosides, this test is also the test of choice for the analysis of samples from patients with CANOMAD syndrome. Tests 1 and 2 were the only methods to offer the detection of anti-GT1a (not included in our own panel). We established in subsequent experiments with Test 1 that antibodies against this particular ganglioside could be a valuable marker of rare GBS variants, e.g., the acute paralysis of the oropharyngeal, neck, and shoulder muscles [24] . Test 1 is also one of the easier to handle and one with a short incubation time among the four tests included in this study. Antigen-band intensity correlates with the antibody titer with a good ratio of background to positive staining. No background membrane staining was visible. Weakly stained bands were not easily interpreted, thus, a quantitative evaluation must be developed to measure band intensity in order to facilitate interpretation.
Regarding the specificity of anti-ganglioside antibody testing, we assessed 50 sera of healthy subjects by our in house assay and Test 1. Except for low positive findings for anti-GM1 in up to 5% of these sera in particular of the IgM isotype, there was no further false positive response detected for the other anti-ganglioside reactivities in these two assays. This is in accordance with the high specificity of anti-ganglioside antibody detection reported elsewhere [15] . The specificities of the other tests need to be determined in a further study.
In conclusion, our findings indicate that specific autoantibody profiles can be detected by validated commercial tests for autoimmune neuropathies using a wide range of glycolipids. Several detected profiles presented even more fine specificities than those observed by our inhouse test previously. These specific anti-ganglioside antibody profiles are very useful to define subgroups of patients, particularly if the clinical or electrophysiological diagnosis is not clear. Despite the enormous effort for standardization of the anti-ganglioside ELISAs made in the early 2000s [25] , our data highlight that there is still a need for extensive standardization of all commercial anti-ganglioside assays.
Internal and external reference standards should be established to facilitate standardization. The implementation of national external quality assessment programs will lead to a further improvement in analytical quality.
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